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Abstract. The streptococcal antitumor agent OK-432 is 
commonly used as an immunopotentiator for immunotherapy 
in various types of malignant tumors including oral cancer. It 
has been demonstrated that OK-432 elicits an antitumor effect 
by stimulating immunocompetent cells, thereby inducing 
multiple cytokines including interferon (IFN)-γ, interleukin 
(IL)-2 and IL-12. Serum concentrations of IFN-γ in patients 
with oral cancer were examined 24 h after administration 
of OK-432. Serum concentrations of IFN-γ in patients with 
advanced cancer were significantly lower than those in patients 
with early cancer. These results suggested that some soluble 
factors produced by cancer cells may inhibit IFN-γ production 
with OK-432. Thus, in the present study, an in vitro simulation 
model was established for the immune status of patients with 
oral cancer by adding conditioned medium (CM) derived from 
oral cancer cell lines into a culture of peripheral blood mono-
nuclear cells (PBMCs) derived from a healthy volunteer. We 
investigated whether soluble factors derived from oral cancer 
cells affected IFN-γ production from PBMCs following stimu-
lation with OK-432. PBMCs stimulated with OK-432 produced 
a large amount of IFN-γ; however, both IFN-γ production 
and cytotoxic activity from PBMCs induced by OK-432 
were inhibited by the addition of CM in a dose-dependent 
manner. In order to examine these inhibitory effects against 
IFN-γ production, the contribution of inhibitory cytokines 
such as IL-4, IL-6, IL-10, transforming growth factor-β and 
vascular endothelial growth factor was investigated. However, 
neutralization of these inhibitory cytokines did not recover 
IFN-γ production inhibited by CM. These results indicated 
that unknown molecules may inhibit IFN-γ production from 
PBMCs following stimulation with OK-432.
Introduction
OK-432 is a penicillin-killed and lyophilized preparation of a 
low-virulence strain (Su) of Streptococcus pyogenes (group A) 
that was developed by Okamoto et al (1). OK-432 is a major 
cancer immunotherapy agent and has been shown to be 
effective against several types of cancer (2-5). We have also 
reported that OK-432 shows a strong antitumor effect against 
oral cancer in combination with radiotherapy and UFT, an oral 
fluoropyrimidine formulation combining tegafur and uracil in 
a 1:4 ratio (6,7).
The main action mechanism of OK-432 is the induction 
and activation of cytotoxic macrophages, cytotoxic T lympho-
cytes, and antitumor effector cells such as natural killer (NK) 
cells and lymphokine-activated killer (LAK) cells. OK-432 
also reportedly increases antitumor effects by increasing 
production of antitumor cytokines such as interferon (IFN)-γ, 
interleukin (IL)-2, IL-12, and tumor necrosis factor (TNF)-α 
by Th1 cells, NK cells, and monocytes/macrophages (8-12), and 
displays antitumor effects by inducing cancer antigen-specific 
cytotoxic T lymphocytes via maturation of antigen-presenting 
dendritic cells (13).
We have successfully isolated a lipoteichoic acid-related 
molecule, OK-PSA, which is an active component of 
OK-432 (14,15). We have also demonstrated that OK-PSA 
exhibits antitumor effects by the induction of antitumor cyto-
kine-producing Th1 cells (16-20). Moreover, we have clarified 
that the receptors against OK-PSA are Toll-like receptor (TLR) 
4/MD-2 complexes that are expressed on the surface of immu-
nocompetent cells (21-24). In addition, when the expression of 
either TLR4 or MD-2 is lost in peripheral blood mononuclear 
cells (PBMCs) in patients with oral cancer, the sensitivity to 
OK-432 is decreased (25). However, after administration of 
OK-432 in patients with oral cancer expressing both TLR4 and 
MD-2, diverse serum concentrations of IFN-γ were detected, 
at ranges of 50-433 pg/ml (Fig. 1). Moreover, serum concentra-
tions of IFN-γ in patients with advanced cancer were lower 
than those in patients with early cancer. These results suggest 
that the responsiveness of OK-432 against patients with oral 
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cancer is dependent on cancer progression and growth. Thus, 
we hypothesized that some types of soluble factors secreted 
by cancer cells may decrease the production of IFN-γ with the 
administration of OK-432.
In the present study, we established an in vitro simula-
tion model for immune status in cancer-burden patients by 
the addition of conditioned medium (CM) derived from oral 
cancer cells to PBMCs derived from healthy volunteers. 
Whether or not soluble factors derived from oral cancer cells 
affected IFN-γ production of PBMCs following stimulation 
with OK-432 was then investigated.
Materials and methods
Investigation of the association between stage of oral 
cancer and serum concentration following OK-432 admin-
istration. We re-analyzed the clinical data described by 
Okamoto et al (25) on the association between serum levels 
of IFN-γ and expression of TLR4 and MD-2 following admin-
istration of OK-432 in patients with oral cancer. According to 
the International Union against Cancer (UICC) criteria (26) 
for tumor-node-metastasis (TNM) classification and cancer 
stage, 4 patients were stage II, 7 were stage III, and 2 were 
stage IV. Patients with oral cancer expressing both TLR4 and 
MD-2 were divided into early cancer (stages I and II) and 
advanced cancer (stages III and IV), and serum levels of IFN-γ 
24 h after administration of OK-432 were compared.
Cells and cell culture. B88 (27) and HNt cells (28), estab-
lished in our laboratory, were derived from patients with oral 
squamous cell carcinoma (SCC), and TYS cells (29) were a 
human oral adenoid squamous carcinoma cell line derived 
from a minor salivary gland in the oral mucosa. All cells 
were maintained in DMEM (Sigma-Aldrich, St. Louis, MO, 
USA) supplemented with 10% (V/V) FBS (Bio-Whittaker, 
Walkersville, MD, USA), 100 µg/ml streptomycin, and 
100 U/ml penicillin (Invitrogen, Carlsbad, CA, USA) in a 
humidified atmosphere of 95% air and 5% CO2 at 37˚C. 
K-562 cells (30), a human erythroblastic leukemic cell line, 
Daudi cells (31), a human Burkitt's lymphoma cell line, and 
PBMCs derived from a healthy volunteer were maintained in 
RPMI-1640 (Sigma-Aldrich) supplemented with 10% FBS.
Preparation of PBMCs. PBMCs were isolated from hepa-
rinized venous blood derived from a healthy volunteer by 
Ficoll-Hypaque gradient density centrifugation according to 
Boyüm's standard procedures (32).
Preparation of CM. Oral cancer cells (2.5x106 cells) were 
grown in 100-mm dishes (Falcon; Becton-Dickinson Labware, 
Lincoln Park, NJ, USA) in complete culture medium for 48 h 
up to attaching the dishes. Then, cells were washed 3 times 
using phosphate-buffered saline (-) and were cultured for an 
additional 72 h in 10 ml of serum-free media. Media were 
collected and purified by passing through 0.2 µm polyether-
sulfone membranes (Corning Costar, Rochester, NY, USA), 
followed by subjection to experiments as CM.
In vitro simulation model of patients with oral cancer. PBMCs 
(1x106 cells/ml) were seeded in RPMI-1640 containing 10% 
FBS. Media were replaced with CM-containing media at 
a CM volume of 1/8, 1/4 or 1/2. FBS and OK-432 (Chugai 
Pharmaceutical, Tokyo, Japan) were added to a final concen-
tration of 10% and 1 µg/ml, respectively.
Enzyme-linked immunosorbent assay (ELISA). Immuno-
suppressive cytokines [IFN-γ, IL-12, IL-4, IL-6, IL-10, 
transforming growth factor-β (TGF-β) and vascular endothe-
lial growth factor (VEGF)] in cell culture supernatant and CM 
were measured by an ELISA kit according to the manufac-
turer's instructions (BioSource International, Inc., Camarillo, 
CA, USA).
Measurement of cytotoxic activities. The cytotoxic activity of 
PBMCs was measured with a lactate dehydrogenase (LDH) 
release assay (33-35) using K-562 cells that exhibited sensitivity 
to human NK and Daudi cells without sensitivity to NK cells 
as target cells. Target cells were suspended in RPMI-1640 
medium containing 1% FBS. After seeding in a proportion of 
5x103 cells/50 µl per well in 96-well round-bottomed micro-
plates (Corning Costar), 1x105 cells/µl of PBMCs were added as 
effector cells. After 4 h of co-culture, the enzymatic activity of 
LDH released from the breakdown of target cells as a result of 
cytotoxic activity was measured using a Cytotoxicity Detection 
Kitplus (Roche Diagnostics GmbH, Mannheim, Germany). 
Cytotoxic activity was calculated using the following formula: 
Cytotoxicity (%) = (A - low control)/(high control - low control) 
x 100; A = (effector-target cell mix - effector cell control).
High control indicates that cells showed absorbance in 
supernatant when Triton X-100 (Sigma-Aldrich) was dissolved 
in target cells. Low control cells showed absorbance in 
supernatant when only target cells were cultured. The effector-
target cell mix shows absorbance in supernatant from a mixed 
culture of effector cells and target cells, and effector cell 
control shows absorbance in supernatant when only effector 
cells were cultured.
Treatment of PBMCs with neutralizing antibodies (Abs). CM 
was treated for 2 h at 37˚C with the following neutralizing Abs; 
anti-IL-4 Ab (clone 3007; 750 ng/ml), anti-IL-6 Ab (clone 6708; 
75 ng/ml), anti-IL-10 Ab (clone 25209; 250 ng/ml), anti-TGF-β 
Ab (clone 27235; 500 ng/ml), or anti-VEGF Ab (clone 26503; 
Figure 1. Association between cancer stage and serum concentration of 
IFN-γ in patients with oral cancer following administration with OK-432. 
Serum concentrations of IFN-γ were examined in patients with oral cancer 
expressing both TLR4 and MD-2, 24 h after OK-432 administration. *P<0.05.
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15 ng/ml) to neutralize each cytokine. After neutralized-CM 
was added to PBMCs, cells were stimulated with OK-432 for 
24 h and then the amount of IFN-γ and IL-12 in culture superna-
tant was measured with an ELISA kit (BioSource International, 
Inc.). All neutralizing antibodies used were purchased from 
R&D Systems (Minneapolis, MN, USA).
Statistical analysis. The data obtained are expressed as the 
means ± standard deviation, using analysis of variance (ANOVA). 
P<0.05 was considered to indicate a statistically significant 
difference.
Results
Association between cancer stage and serum concentration 
of IFN-γ in patients with oral cancer following administra-
tion of OK-432. Twenty-four hours after the administration 
of OK-432, serum concentrations of IFN-γ in patients with 
advanced cancer were significantly lower than those in patients 
with early cancer (Fig. 1).
Effect of CM on the expression of IFN-γ mRNA in PBMCs 
following treatment with OK-432. IFN-γ mRNA expression of 
PBMCs increased following stimulation with OK-432, but was 
significantly inhibited after replacement of CM-containing 
media at a CM (derived from B88 cells) volume of 1/2 (Fig. 2).
Effect of CM on IFN-γ production from PBMCs following 
treatment with OK-432. IFN-γ produced by PBMCs increased 
after stimulation with OK-432, but decreased in the presence 
of CM in a CM concentration-dependent manner. Inhibition 
of IFN-γ production from PBMCs in the presence of CM was 
detected in all oral cancer cells used (Fig. 3).
Effect of CM on the cytotoxic activity of PBMCs following 
treatment with OK-432. Cytotoxic activities of PBMCs against 
K-562 cells (Fig. 4A) and Daudi cells (Fig. 4B) were enhanced 
in both cells following treatment with OK-432; however, 
activities were significantly inhibited after replacement of 
CM-containing media at a CM (derived from B88 cells) 
volume of 1/2 (Fig. 4).
Effect of immunosuppressive cytokines on IFN-γ production 
from PBMCs following treatment with OK-432. Table I shows 
the concentration of each cytokine in CM derived from B88, 
TYS, and HNt cells. Of these cytokines, neutralization tests 
against representative immunosuppressive cytokines, IL-4, 
IL-6, IL-10, TGF-β and VEGF, were conducted to elucidate 
the inhibitory mechanism of IFN-γ production from PBMCs 
in the presence of CM. Despite the addition of CM derived 
from B88 cells and TYS cells pretreated with neutralizing 
Abs against these immunosuppressive cytokines, inhibition of 
IFN-γ production from PBMCs was not restored (Fig. 5). By 
the addition of neutralizing Abs against IL-6 and VEGF to 
Figure 3. Effect of CM on IFN-γ production from PBMCs following stimu-
lation with OK-432. In the presence of CM, PBMCs were stimulated with 
OK-432 for 24 h, and then the concentration of IFN-γ was examined by ELISA. 
(A) B88 cells, (B) TYS cells, (C) HNt cells. ***P<0.001. ND, not detectable.
Figure 2. Effect of CM on IFN-γ mRNA expression in PBMCs following 
stimulation with OK-432. In the presence of CM, PBMCs were stimulated 
with OK-432 for 24 h, and then the expression of IFN-γ mRNA was 
analyzed by RT-PCR. Densitometric analysis for the RT-PCR band was 
performed using ImageJ 1.38 software (National Institutes of Health, 
Bethesda, MD, USA).
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CM derived from TYS cells, inhibition of IFN-γ production 
from PBMCs appears to have been restored (Fig. 5B and E). 
However, induction of IFN-γ production from PBMCs was 
also observed only with the addition of neutralizing antibody 
in the absence of CM. These results indicate that IL-6 and 
VEGF are likely not the main cytokines affecting the inhibi-
tion of IFN-γ production from PBMCs with CM.
Discussion
In the present study, we established an in vitro simulation 
model for immune status in cancer-burden patients by the 
addition of CM derived from oral cancer cells to PBMCs 
isolated from a healthy volunteer. Whether or not soluble 
factors derived from oral cancer cells affected IFN-γ produc-
tion from PBMCs following stimulation with OK-432 was 
then investigated. We found that, in the presence of CM, 
enhanced production of IFN-γ and cytotoxic activities of 
PBMCs following stimulation with OK-432 decreased in a 
CM concentration-dependent manner. Although IL-4, IL-6, 
IL-10, TGF-β and VEGF were representative immunosup-
pressive cytokines that play critical roles in the inhibition of 
IFN-γ production, they did not contribute to the inhibition of 
IFN-γ production by CM.
In general, diverse immunosuppressive cytokines produced 
by cancer cells are known to contribute to the immune suppres-
sion of patients with cancer. For example, IL-6 is generally 
released by macrophages, but is also produced by cancer cells, 
which inhibits production of IFN-γ from PBMCs (36). In the 
present study, high levels of IL-6 production were detected 
in all oral cancer cells used. It was also reported that the 
immunosuppressive status of patients with cancer caused by 
cachexia is induced by inhibition of IFN-γ and acceleration 
of IL-6 production. TGF-β is also known as an immunosup-
pressive cytokine produced by several types of cancer cells. 
It was demonstrated that by the neutralization of TGF-β in 
CM and the addition of recombinant TGF-β, the immunosup-
pressive effect of TGF-β was based on the inhibition of CD4+ 
T-cell function (37). It was also clarified that TGF-β in CM 
suppressed IFN-γ production from PBMCs using pancreatic 
and liver cancer cells (38,39). It is well known that VEGF is 
also secreted from cancer cells and stimulates growth and 
metastasis of cancer via angiogenesis. The immunosuppres-
sive effects of VEGF are considered to occur by blocking 
the differentiation of bone marrow stem cells into dendritic 
cells and the maturation of dendritic cells and by inhibiting 
the antigen-presenting ability and cytokine production of 
dendritic cells (40,41). The oral cancer cells used in the present 
study also secreted these representative immunosuppressive 
cytokines; however, these cytokines were not involved in the 
inhibition of IFN-γ production from PBMCs by CM.
Immunosuppressive cytokines produced by PBMCs stimu-
lated by cancer cell-derived soluble factors are also known 
to induce immunosuppression of patients with cancer. It has 
been reported that CM from kidney cancer cells or malignant 
melanoma cells enhanced the production of immunosuppres-
sive cytokines such as IL-4, IL-6 and IL-10 by PBMCs (42,43). 
IL-10 is also known to be produced by PBMCs that are stimu-
lated by OK-432 (44), followed by the inhibition of IFN-γ 
production (45). In the present study, IL-10 levels were not 
detectable in CM derived from oral cancer cells, but were 
markedly induced by stimulation of OK-432, and were further 
induced with the addition of CM (data not shown). However, 
even if IL-10 is blocked by the neutralizing Ab, inhibition of 
IFN-γ production from PBMCs by the addition of CM could 
not recover. Among the other immunosuppressive cytokines 
investigated in the present study, production of IL-4, TGF-β, 
or VEGF was not detected in PBMCs even after stimulation 
with OK-432 (data not shown). While production of IL-6 was 
Table I. Concentration of cytokines in CM from oral cancer 
cell lines (pg/ml).
Cells IFN-γ IL-12 IL-4 IL-6 IL-10 TGF-β VEGF
B88 ND 28.4 34.5   910 ND 107 4662
TYS ND 23.8 23.4 1437 ND 113 5019
HNt ND 24.4 - 1385 ND   70 3891
CM, conditioned medium; IFN-γ, interferon-γ; IL, interleukin; 
TGF-β, transforming growth factor-β; VEGF, vascular endothelial 
growth factor; ND, not detectable; -, not done.
Figure 4. Effect of CM on the cytotoxic activity of PBMCs following 
stimulation with OK-432. In the presence of CM, PBMCs were stimulated 
with OK-432 for 24 h, and then the cytotoxic activities of PBMCs against 
K-562 (A) and Daudi (B) cells were examined by the LDH assay. *P<0.05; 
***P<0.001. ND, not detectable.
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Figure 5. Effect of cytokines on IFN-γ production from PBMCs following stimulation with OK-432. In the presence of CM pretreated with neutralizing Ab 
against (A) IL-4, (B) IL-6, (C) IL-10, (D) TGF-β or (E) VEGF, PBMCs were stimulated with OK-432 for 24 h, and then the concentration of IFN-γ in the 
supernatant was examined by ELISA. *P<0.05; ***P<0.001. NS, not significant.
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induced in PBMCs following stimulation with OK-432 (data 
not shown), IFN-γ production from PBMCs inhibited by the 
addition of CM following stimulation with OK-432 did not 
recover even by the neutralization of IL-6. We thus concluded 
that representative immunosuppressive cytokines produced by 
cancer cells or PBMCs are not involved in the suppression of 
IFN-γ production from PBMCs by the addition of CM. These 
results suggest that unknown molecules, excluding these repre-
sentative immunosuppressive cytokines, may be involved in 
the inhibition of IFN-γ production. Clarifying these unknown 
molecules may be a way to develop effective immunotherapy 
against oral cancer.
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